

CORRECTION

# Correction to: Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis

Sue Ping Thang<sup>1,3</sup> · Mei Sim Lung<sup>2</sup> · Grace Kong<sup>1</sup> · Michael S. Hofman<sup>1</sup> · Jason Callahan<sup>1</sup> · Michael Michael<sup>2</sup> · Rodney J. Hicks<sup>1</sup>

Published online: 20 November 2017  
© Springer-Verlag GmbH Germany, part of Springer Nature 2017

**Correction to: European Journal of Nuclear Medicine and Molecular Imaging**

<https://doi.org/10.1007/s00259-017-3821-2>

On page 4 of the original version of this article, the text "Eight (29%) of the patients had significant FDG-avid disease (i.e. with intensity above liver parenchyma) prior to treatment" needs to be corrected to "Eighty-nine percent of the patients had significant FDG-avid disease (i.e. with intensity above liver parenchyma) prior to treatment".

---

The online version of the original article can be found at <https://doi.org/10.1007/s00259-017-3821-2>

---

✉ Rodney J. Hicks  
Rod.Hicks@petermac.org

<sup>1</sup> Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

<sup>2</sup> Division of Cancer Medicine, Neuroendocrine Tumour Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

<sup>3</sup> Department of Nuclear Medicine and PET, Singapore General Hospital, Singapore, Singapore